Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98 - PubMed (original) (raw)
Clinical Trial
. 2007 Sep 1;25(25):3846-52.
doi: 10.1200/JCO.2007.11.9453. Epub 2007 Aug 6.
Meredith M Regan, Eugenio Maiorano, Mauro G Mastropasqua, Patrizia Dell'Orto, Birgitte Bruun Rasmussen, Johnny Raffoul, Patrick Neven, Zsolt Orosz, Stephen Braye, Christian Ohlschlegel, Beat Thürlimann, Richard D Gelber, Monica Castiglione-Gertsch, Karen N Price, Aron Goldhirsch, Barry A Gusterson, Alan S Coates
Affiliations
- PMID: 17679725
- DOI: 10.1200/JCO.2007.11.9453
Clinical Trial
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
Giuseppe Viale et al. J Clin Oncol. 2007.
Abstract
Purpose: To evaluate locally versus centrally assessed estrogen (ER) and progesterone (PgR) receptor status and the impact of PgR on letrozole adjuvant therapy compared with tamoxifen in postmenopausal women with early breast cancer.
Patients and methods: Breast International Group (BIG) 1-98 randomly assigned 8,010 patients to four arms comparing letrozole and tamoxifen with sequences of each agent. The Central Pathology Office received material for 6,549 patients (82%), of which 79% were assessable (6,291 patients). Prognostic and predictive value of both local and central hormone receptor expression on disease-free survival (DFS) were evaluated among 3,650 assessable patients assigned to the monotherapy arms. Prognostic value and the treatment effect were estimated for centrally assessed ER and PgR expression levels using the Subpopulation Treatment Effect Pattern Plot.
Results: Central review confirmed 97% of tumors as hormone receptor-positive (ER and/or PgR > or =10%). Of 105 tumors locally ER-negative, 73 were found to have more than 10% positive cells, and eight had 1% to 9%. Of 6,100 tumors locally ER positive, 66 were found to have no staining, and 54 had only 1% to 9%. Discordance was more marked for PgR than ER. Patients with tumors reclassified centrally as ER-negative, or as hormone receptor-negative, had poor DFS. Centrally assessed ER and PgR showed prognostic value. Among patients with centrally assessed ER-expressing tumors, letrozole showed better DFS than tamoxifen, irrespective of PgR expression level.
Conclusion: Central review changed the assessment of receptor status in a substantial proportion of patients, and should be performed whenever possible in similar trials. PgR expression did not affect the relative efficacy of letrozole over tamoxifen.
Similar articles
- Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL; National Cancer Institute of Canada Clinical Trials Group MA.17. Goss PE, et al. J Clin Oncol. 2007 May 20;25(15):2006-11. doi: 10.1200/JCO.2006.09.4482. Epub 2007 Apr 23. J Clin Oncol. 2007. PMID: 17452676 Clinical Trial. - Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Viale G, et al. J Clin Oncol. 2008 Mar 20;26(9):1404-10. doi: 10.1200/JCO.2007.10.6393. J Clin Oncol. 2008. PMID: 18349391 Clinical Trial. - Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. Coates AS, et al. J Clin Oncol. 2007 Feb 10;25(5):486-92. doi: 10.1200/JCO.2006.08.8617. Epub 2007 Jan 2. J Clin Oncol. 2007. PMID: 17200148 Clinical Trial. - Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM. Wardley AM. Adv Ther. 2008 Dec;25(12):1257-75. doi: 10.1007/s12325-008-0128-5. Adv Ther. 2008. PMID: 19096768 Review. - The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM. Monnier AM. Expert Rev Anticancer Ther. 2007 May;7(5):627-34. doi: 10.1586/14737140.7.5.627. Expert Rev Anticancer Ther. 2007. PMID: 17492927 Review.
Cited by
- Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up.
Fohlin H, Nordenskjöld A, Rosell J, Fernö M, Fornander T, Rydén L, Skoog L, Nordenskjöld B, Stål O. Fohlin H, et al. Acta Oncol. 2024 Jul 5;63:535-541. doi: 10.2340/1651-226X.2024.40493. Acta Oncol. 2024. PMID: 38967128 Free PMC article. Clinical Trial. - Clinical considerations for estrogen receptor-negative/progesterone receptor-positive/HER2-negative (ER-PR+HER2-) breast cancer.
Rala de Paula BH, Crocamo S, Bines J. Rala de Paula BH, et al. Transl Breast Cancer Res. 2022 Oct 28;4:8. doi: 10.21037/tbcr-22-41. eCollection 2023. Transl Breast Cancer Res. 2022. PMID: 38751458 Free PMC article. No abstract available. - Comprehensive multi-level expression profiling of key biomarkers in breast cancer patients.
Zia T, Bangfan L, Nadeem A, Hussain A, Abdel-Maksoud MA, Zakri AM, Bashir MK, Ali M, Jabeen N, Jamil M, Al-Qahtani WH, Almanaa TN. Zia T, et al. Am J Transl Res. 2023 Oct 15;15(10):6058-6070. eCollection 2023. Am J Transl Res. 2023. PMID: 37969199 Free PMC article. - Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers.
Chen HL, Huang FB, Chen Q, Deng YC. Chen HL, et al. BMC Cancer. 2023 Sep 8;23(1):841. doi: 10.1186/s12885-023-11368-2. BMC Cancer. 2023. PMID: 37684569 Free PMC article. - Advancing Breast Cancer Heterogeneity Analysis: Insights from Genomics, Transcriptomics and Proteomics at Bulk and Single-Cell Levels.
Zhu Z, Jiang L, Ding X. Zhu Z, et al. Cancers (Basel). 2023 Aug 18;15(16):4164. doi: 10.3390/cancers15164164. Cancers (Basel). 2023. PMID: 37627192 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials